Literature DB >> 29496669

Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas.

Alexandra Nagy1, Aparna Bhaduri2, Nahid Shahmarvand1, Jahanbanoo Shahryari1, James L Zehnder1, Roger A Warnke1, Tariq Mughal3,4, Siraj Ali3, Robert S Ohgami1.   

Abstract

Castleman disease (CD) is a rare lymphoproliferative disorder subclassified as unicentric CD (UCD) or multicentric CD (MCD) based on clinical features and the distribution of enlarged lymph nodes with characteristic histopathology. MCD can be further subtyped based on human herpes virus 8 (HHV8) infection into HHV8-associated MCD, HHV8-/idiopathic MCD (iMCD), and polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin change (POEMS)-associated MCD. In a subset of cases of UCD, an associated follicular dendritic cell sarcoma (FDCS) may be seen. Although numerous reports of the clinical and histologic features of UCD, MCD, and FDCS exist, an understanding of the genetic and epigenetic landscape of these rare diseases is lacking. Given this paucity of knowledge, we analyzed 15 cases of UCD and 3 cases of iMCD by targeted next-generation sequencing (NGS; 405 genes) and 3 cases of FDCS associated with UCD hyaline vascular variant (UCD-HVV) by whole-exome sequencing. Common amplifications of ETS1, PTPN6, and TGFBR2 were seen in 1 iMCD and 1 UCD case; the iMCD case also had a somatic DNMT3A L295Q mutation. This iMCD patient also showed clinicopathologic features consistent with a specific subtype known as Castleman-Kojima disease (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly [TAFRO] clinical subtype). Additionally, 1 case of UCD-HVV showed amplification of the cluster of histone genes on chromosome 6p. FDCS associated with UCD-HVV showed mutations and copy number changes in known oncogenes, tumor suppressors, and chromatin structural-remodeling proteins.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2018        PMID: 29496669      PMCID: PMC5851414          DOI: 10.1182/bloodadvances.2017009654

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  49 in total

Review 1.  The transcription factor ETS1 in lymphomas: friend or foe?

Authors:  Monica Testoni; Elaine Yee Lin Chung; Valdemar Priebe; Francesco Bertoni
Journal:  Leuk Lymphoma       Date:  2015-01-14

Review 2.  The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care.

Authors:  Corey Casper
Journal:  Br J Haematol       Date:  2005-04       Impact factor: 6.998

3.  Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF.

Authors:  Takahiro Maeda; Taha Merghoub; Robin M Hobbs; Lin Dong; Manami Maeda; Johannes Zakrzewski; Marcel R M van den Brink; Arthur Zelent; Hirokazu Shigematsu; Koichi Akashi; Julie Teruya-Feldstein; Giorgio Cattoretti; Pier Paolo Pandolfi
Journal:  Science       Date:  2007-05-11       Impact factor: 47.728

4.  STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression.

Authors:  Robert S Ohgami; Lisa Ma; Ahmad Monabati; James L Zehnder; Daniel A Arber
Journal:  Haematologica       Date:  2014-05-16       Impact factor: 9.941

5.  Indolent T-lymphoblastic proliferation with disseminated multinodal involvement and partial CD33 expression.

Authors:  Robert S Ohgami; Anoop K Sendamarai; Susan K Atwater; Michaela Liedtke; Mark D Fleming; Yasodha Natkunam; Roger A Warnke
Journal:  Am J Surg Pathol       Date:  2014-09       Impact factor: 6.394

6.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

Authors:  Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

7.  Higher stromal expression of transforming growth factor-beta type II receptors is associated with poorer prognosis breast tumors.

Authors:  John Barlow; David Yandell; Donald Weaver; Theresa Casey; Karen Plaut
Journal:  Breast Cancer Res Treat       Date:  2003-05       Impact factor: 4.872

8.  Overexpression of the protein tyrosine phosphatase, nonreceptor type 6 (PTPN6), in human epithelial ovarian cancer.

Authors:  S C Mok; T T Kwok; R S Berkowitz; A J Barrett; F W Tsui
Journal:  Gynecol Oncol       Date:  1995-06       Impact factor: 5.482

9.  Structural and histone binding ability characterizations of human PWWP domains.

Authors:  Hong Wu; Hong Zeng; Robert Lam; Wolfram Tempel; Maria F Amaya; Chao Xu; Ludmila Dombrovski; Wei Qiu; Yanming Wang; Jinrong Min
Journal:  PLoS One       Date:  2011-06-20       Impact factor: 3.240

10.  A study of the mutational landscape of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma.

Authors:  Michael G Ozawa; Aparna Bhaduri; Karen M Chisholm; Steven A Baker; Lisa Ma; James L Zehnder; Sandra Luna-Fineman; Michael P Link; Jason D Merker; Daniel A Arber; Robert S Ohgami
Journal:  Mod Pathol       Date:  2016-06-24       Impact factor: 7.842

View more
  11 in total

Review 1.  Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Predictive Model for Idiopathic Multicentric Castleman Disease Supporting Treatment Decisions.

Authors:  Xiaosheng Fang; Zhongling Sun; Zijun Y Xu-Monette; Ken H Young
Journal:  Oncologist       Date:  2020-11-30

Review 3.  Castleman disease.

Authors:  Antonino Carbone; Margaret Borok; Blossom Damania; Annunziata Gloghini; Mark N Polizzotto; Raj K Jayanthan; David C Fajgenbaum; Mark Bower
Journal:  Nat Rev Dis Primers       Date:  2021-11-25       Impact factor: 65.038

4.  Transcriptome and unique cytokine microenvironment of Castleman disease.

Authors:  Anna Wing; Jason Xu; Wenzhao Meng; Aaron M Rosenfeld; Elizabeth Y Li; Gerald Wertheim; Michele Paessler; Adam Bagg; Dale Frank; Kai Tan; David T Teachey; Megan S Lim; Eline Luning Prak; David C Fajgenbaum; Vinodh Pillai
Journal:  Mod Pathol       Date:  2021-10-22       Impact factor: 8.209

5.  Intra-abdominal inflammatory pseudotumor-like follicular dendritic cell sarcoma associated with paraneoplastic pemphigus: A case report and review of the literature.

Authors:  Jia-Yi Zhuang; Fang-Fei Zhang; Qing-Wen Li; Yong-Feng Chen
Journal:  World J Clin Cases       Date:  2020-07-26       Impact factor: 1.337

Review 6.  Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum
Journal:  Blood       Date:  2018-11-29       Impact factor: 22.113

7.  Histologic and Laboratory Characteristics of Symptomatic and Asymptomatic Castleman Disease in the Pediatric Population.

Authors:  Karen M Chisholm; Mark D Fleming
Journal:  Am J Clin Pathol       Date:  2020-05-05       Impact factor: 2.493

8.  DNMT3A haploinsufficiency causes dichotomous DNA methylation defects at enhancers in mature human immune cells.

Authors:  Jung-Yeon Lim; Sascha H Duttke; Turner S Baker; Jihye Lee; Kristyne J Gambino; Nicholas J Venturini; Jessica Sook Yuin Ho; Simin Zheng; Yesai S Fstkchyan; Vinodh Pillai; David C Fajgenbaum; Ivan Marazzi; Christopher Benner; Minji Byun
Journal:  J Exp Med       Date:  2021-05-10       Impact factor: 17.579

Review 9.  Interleukin-17 receptor D (Sef) is a multi-functional regulator of cell signaling.

Authors:  Shivangi Pande; Xuehui Yang; Robert Friesel
Journal:  Cell Commun Signal       Date:  2021-01-12       Impact factor: 5.712

Review 10.  A Review of Genetic Abnormalities in Unicentric and Multicentric Castleman Disease.

Authors:  Alexandra Butzmann; Jyoti Kumar; Kaushik Sridhar; Sumanth Gollapudi; Robert S Ohgami
Journal:  Biology (Basel)       Date:  2021-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.